Acute Coronary Syndrome Clinical Trial
— ALERTSOfficial title:
AngelMed for Early Recognition and Treatment of STEMI
Verified date | March 2018 |
Source | Angel Medical Systems |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A prospective, randomized multicenter study of subjects with a high-risk of having a myocardial infarction (MI) due to acute coronary syndrome or bypass surgery. There is no differential intervention administered to the two arms of the ALERTS Study. The study evaluates whether or not a patient alarm from the Guardian System will provide benefit (e.g. shorten pre-hospital delay) compared to symptoms-only ER presentation in the event of a heart attack. An amendment to the data analysis protocol was collaboratively created by AngelMed and FDA, and was adopted by AngelMed on 4/22/2017.
Status | Completed |
Enrollment | 1020 |
Est. completion date | May 17, 2017 |
Est. primary completion date | May 1, 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: - Subject has at least one of the following conditions: 1. Diabetes (Type I or Type II) 2. Compromised renal function (Cr > 1.2 mg/dl or creatinine clearance less than 50) 3. TIMI Risk Score = 3 - Presents (within past 6 months) with a high-risk acute coronary syndrome (e.g., Unstable Angina, STEMI or NSTEMI) or has undergone or is scheduled for CABG within 6 months of implantation. - Has already undergone coronary angiography and revascularization, unless the physician determines it is appropriate to implant before or during the planned procedure. - Lives in a geographic area in close proximity (within 60 minutes by EMS) to any hospital that can treat AMI. - Subjects (men or women) at least 21 years of age. Women of childbearing age must have a negative pregnancy test or confirmation of one of the following: 1. Post-menopause or amenorrheic during the past year 2. Surgical sterilization 3. Use of effective contraceptive method Exclusion Criteria: - In the investigator's opinion, subject lacks ability to respond appropriately to alarms, e.g., illiteracy, poor memory or cognitive function, dementia or other condition affecting memory function, etc. - There is known compromised tissue at the site of lead implantation in the apex of the right ventricle, e.g., prior infarct affecting the RV apex location. - A permanent pacemaker or ICD is already in place or the patient is indicated for ICD or pacemaker implantation based on the guidelines published by the American College of Cardiology as Class I and IIa recommendations. Class IIb recommendations are at the investigator's discretion. - Subject cannot feel the IMD vibration when placed on top of the skin on the left pectoral side of the chest. - Subject has recurrent or persistent atrial fibrillation. - Subject has recurrent or persistent non-sinus cardiac rhythm, second or third degree atrioventricular blocks, QRS duration greater than 120 ms, Benign Early Repolarization (BER), or Brugada Syndrome. - Subject has left ventricular hypertrophy evidenced by EKG criteria. - Subject has any condition preventing the subcutaneous implantation of the Guardian System in a left pectoral pouch, such as: superior vena cava thrombosis, subcutaneous tissue deemed inappropriate for the procedure or prior central venous access via portacath, Hickman, Groshong, or similar placed in a left pectoral location or left side PICC line. - Subject has extremely heavy alcohol consumption (participates in binge drinking that leads to alcohol intoxication) or has history of alcohol or illicit drug abuse within past 5 years. - There is evidence of unresolved infection (fever > 38° C and/or leukocytosis > 15,000). - Subject has history of bleeding disorders or severe coagulopathy (platelets < 100,000 plts/ml; APTT or PT > 1.3 x reference range). - Subject has had a hemorrhagic stroke or transient ischemic attack (TIA) in the past 6 months. - Subject has other severe diseases, such as cancer or refractory congestive heart failure, associated with limitation of life expectancy (less than 1 year), which may lead to inadequate compliance to the protocol or confusing data interpretation. - Subject has clinical conditions such as heart diseases, difficult-to-control blood pressure, difficult-to-control insulin-dependent diabetes or serious prior infections attributed to the diabetes, or others that, at the investigator's discretion, could seriously affect the subject's current clinical condition during study procedures. - Subject has previous participation in the DETECT Study, current participation or previous participation in another drug or device study in the past 30 days that conflicts with this study as determined by the study sponsor. - Subject has experienced gastro-intestinal hemorrhage in the past 6 months. - Subject has any situation in which the use of aspirin is contraindicated for at least 6 months. - Subject has epilepsy. - Subject has known severe allergies, e.g., peanut, bee sting, etc. |
Country | Name | City | State |
---|---|---|---|
United States | Albany Associates in Cardiology | Albany | New York |
United States | Cardiology Center of Amarillo | Amarillo | Texas |
United States | AnMed Health | Anderson | South Carolina |
United States | MedStar Health Research Institute | Baltimore | Maryland |
United States | University of Maryland Medical Center | Baltimore | Maryland |
United States | McLaren Bay Region | Bay City | Michigan |
United States | Bay Pines VA Healthcare System | Bay Pines | Florida |
United States | Suburban Hospital - Johns Hopkins Medicine | Bethesda | Maryland |
United States | Cardiology, P.C. | Birmingham | Alabama |
United States | Premier Healthcare | Bloomington | Indiana |
United States | SUNY Downstate Medical Center | Brooklyn | New York |
United States | Buffalo Heart Group - Mercy Hospital of Buffalo | Buffalo | New York |
United States | Buffalo Heart Group - Millard Fillmore Gates Circle Hospital | Buffalo | New York |
United States | Northwestern University | Chicago | Illinois |
United States | John Muir Clinical Research Center | Concord | California |
United States | Innovative Medical Research | Covington | Louisiana |
United States | Geisinger Medical Center | Danville | Pennsylvania |
United States | Good Samaritan Hospital | Dayton | Ohio |
United States | Daytona Heart Group | Daytona Beach | Florida |
United States | DMC Cardiovascular Institute at Harper-Hutzel Hospital | Detroit | Michigan |
United States | Detroit Clinical Research Center | Farmington Hills | Michigan |
United States | Cardiology Consultants of East Michigan | Flint | Michigan |
United States | Holy Cross Hospital | Fort Lauderdale | Florida |
United States | Northern Indiana Research Alliance | Fort Wayne | Indiana |
United States | Cardiology Associates of Fredericksburg | Fredericksburg | Virginia |
United States | NorthFL/South GA VA Health System | Gainesville | Florida |
United States | Stern Cardiovascular Center | Germantown | Tennessee |
United States | California Clinical Research Foundation | Glendale | California |
United States | Genesys Regional Medical Center | Grand Blanc | Michigan |
United States | Spectrum Health | Grand Rapids | Michigan |
United States | Greenville Hospital System | Greenville | South Carolina |
United States | Heart Clinic of Hammond | Hammond | Louisiana |
United States | Penn State Hershey Medical Center | Hershey | Pennsylvania |
United States | West Houston Area Clinical Trial Consultants | Houston | Texas |
United States | West Houston Area Clinical Trial Consultants | Houston | Texas |
United States | Heart Center Research/Huntsville Hospital | Huntsville | Alabama |
United States | Borgess Medical Center | Kalamazoo | Michigan |
United States | Turkey Creek Medical Center | Knoxville | Tennessee |
United States | Lancaster General Hospital | Lancaster | Pennsylvania |
United States | St. Mary Medical Center Research Institute | Langhorne | Pennsylvania |
United States | Sparrow Clinical Research Institute | Lansing | Michigan |
United States | Central Baptist Hospital | Lexington | Kentucky |
United States | Long Beach Memorial Medical Center | Long Beach | California |
United States | The Medical Center of Central Georgia | Macon | Georgia |
United States | Virginia Cardiovascular Associates | Manassas | Virginia |
United States | Heart Center of Lake County | Merrillville | Indiana |
United States | Banner Heart Hospital | Mesa | Arizona |
United States | Mercy Research Institute | Miami | Florida |
United States | University of Miami | Miami | Florida |
United States | New Phase Clinical Trials | Miami Beach | Florida |
United States | Mission Internal Medical Group | Mission Viejo | California |
United States | McLaren Macomb | Mount Clemens | Michigan |
United States | Medical Consultants, PC | Muncie | Indiana |
United States | St. Thomas Research Institute | Nashville | Tennessee |
United States | Jersey Shore University Medical Center | Neptune | New Jersey |
United States | University of Medicine & Dentistry NJ | New Brunswick | New Jersey |
United States | Complete Cardiology Care | New Smyrna Beach | Florida |
United States | Columbia University Medical Center | New York | New York |
United States | St. Michael's Medical Center | Newark | New Jersey |
United States | Riverside Regional Medical Center | Newport News | Virginia |
United States | Sentara Cardiovascular Research Institute | Norfolk | Virginia |
United States | South Oklahoma Heart Research | Oklahoma City | Oklahoma |
United States | Orange County Heart Institute and Research Center Hospital | Orange | California |
United States | Advocate Medical Group | Park Ridge | Illinois |
United States | Huntington Memorial Hospital | Pasadena | California |
United States | Cardiac & Vascular Research Center of Northern Michigan | Petoskey | Michigan |
United States | Drexel University College of Medicine | Philadelphia | Pennsylvania |
United States | Banner Good Samaritan Medical Center | Phoenix | Arizona |
United States | Woodholme Cardiovacular Associates | Pikesville | Maryland |
United States | Allegheny-Singer Research Institute | Pittsburgh | Pennsylvania |
United States | REX Healthcare | Raleigh | North Carolina |
United States | Mayo Clinic | Rochester | Minnesota |
United States | Sutter Memorial Hospital | Sacramento | California |
United States | University of California Davis Medical Center | Sacramento | California |
United States | East Coast Institute for Research | Saint Augustine | Florida |
United States | Salinas Valley Memorial Hospital | Salinas | California |
United States | Radiant Research | Santa Rosa | California |
United States | Donald Guthrie Foundation for Education & Research | Sayre | Pennsylvania |
United States | Swedish Medical Center/Cardiovascular Research | Seattle | Washington |
United States | Louisiana Heart Center | Slidell | Louisiana |
United States | Stony Brook University Medical Center | Stony Brook | New York |
United States | Washington Adventist Hospital | Takoma Park | Maryland |
United States | Florida Hospital - Pepin Heart Institute | Tampa | Florida |
United States | Univeristy of South Florida | Tampa | Florida |
United States | Scott and White Healthcare | Temple | Texas |
United States | Cardiovascular Research Center | Toledo | Ohio |
United States | University of Toledo | Toledo | Ohio |
United States | Southwest Heart Group | Tucson | Arizona |
United States | Tyler Cardiovascular Consultants | Tyler | Texas |
United States | Cardiovascular Associates, Ltd | Virginia Beach | Virginia |
United States | Lourdes Cardiology Services | Voorhees | New Jersey |
United States | Washington Hospital Center | Washington | District of Columbia |
United States | Geisinger Wyoming Valley Heart Hospital | Wilkes-Barre | Pennsylvania |
United States | Cardiology Group of Western New York | Williamsville | New York |
United States | Cardiac Diagnostic Associates/York Hospital | York | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Angel Medical Systems | Symbios Clinical |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary efficacy objective is to determine that the Guardian System reduces the composite of Cardiac or unexplained death, new Q-wave MI and time to door for a confirmed occlusive event at a medical facility >2 hours. | With Amendment the primary efficacy objective was amended to be a co-primary endpoint which included A) a hypothesis test of superiority for positive predictive value of ER visits in the ALARMS_ON group due to Guardian alerting (with or without concurrent symptoms) compared to ER visits in the ALARMS_OFF group due to symptoms only; AND B) a hypothesis test of non-inferiority for rate of false positive ER visits in the ALARMS_ON group due to Guardian alerting (with or without concurrent symptoms) compared to rate of false positive ER visits in the ALARMS_OFF group due to symptoms only. | Due to Bayesian statistical analysis, the study data will be analyzed after subject enrollment reaches 600, 900, 1200, etc. With amendment the study period spanned from December 2008 until database lock April 1, 2014. | |
Secondary | - Reduction of the incidence of cardiac death or unexplained death during follow-up - Reduction of the incidence of "New" Q-wave myocardial infarction in one or more distributions during follow-up- Reduction of the time to door for confirmed STEMI. | With Amendment the secondary efficacy endpoint measures were amended to include Endpoint #1) a hypothesis test of superiority for rate of false positive ER visits in the ALARMS_ON group due to Guardian alerting (with or without concurrent symptoms) compared to rate of false positive ER visits in the ALARMS_OFF group due to symptoms only. | Due to Bayesian statistical analysis, the study data will be analyzed after subject enrollment reaches 600, 900, 1200, etc With amendment the study period spanned from December 2008 until database lock April 1, 2014. | |
Secondary | Secondary Endpoint #2 | With Amendment the secondary efficacy endpoint measures were amended to include Endpoint #2) The number of Silent MIs, the percentage in relation to total MIs in the ALARMS ON group, and the percentage of subjects experiencing Silent MIs will be reported (no hypotheses existed for this endpoint) | With amendment the study period spanned from December 2008 until database lock April 1, 2014. | |
Secondary | Secondary Endpoint #3 | With Amendment the secondary efficacy endpoint measures were amended to include Endpoint #3) Descriptive statistics for the median, average and distribution of symptom-to-door and alarm-to-door times for STEMI events and the number and percentage of subjects with time-to-door times of < 2 hours will be reported for both the ALARMS ON and ALARMS OFF groups (no hypotheses existed for this endpoint). | With amendment the study period spanned from December 2008 until database lock April 1, 2014. | |
Secondary | Secondary Endpoint #4 | With Amendment the secondary efficacy endpoint measures were amended to include Endpoint #4) The time that elapses between the initial patient prompt (alarm or symptom) and arrival at a medical facility will be calculated for all subjects who suffered a STEMI or NSTEMI, and had an associated Guardian alarm (no hypotheses existed for this endpoint). | With amendment the study period spanned from December 2008 until database lock April 1, 2014. | |
Secondary | Secondary Endpoint #5 | With Amendment the secondary efficacy endpoint measures were amended to include Endpoint #5: The time that elapses between the initial patient prompt (Alarm or Symptom) and arrival at a medical facility will be calculated for all subjects who suffered an ACS event (STEMI, NSTEMI, or Unstable Angina), and had an associated Guardian System alarm (with or without symptoms) (no hypotheses existed for this endpoint). | With amendment the study period spanned from December 2008 until database lock April 1, 2014. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06013813 -
Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT05412927 -
AngelMed Guardian® System PMA Post Approval Study
|
||
Completed |
NCT02750579 -
Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?
|
N/A | |
Completed |
NCT04102410 -
Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients
|
N/A | |
Enrolling by invitation |
NCT03342131 -
Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome
|
N/A | |
Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
Enrolling by invitation |
NCT04676100 -
International CR Registry
|
||
Completed |
NCT03590535 -
5th Generation cTnT in ED ACS
|
||
Recruiting |
NCT05437900 -
INSIGHTFUL-FFR Clinical Trial
|
Phase 4 | |
Completed |
NCT05551429 -
Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
|
||
Terminated |
NCT04316481 -
IDE-ALERTS Continued Access Study
|
N/A | |
Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
Not yet recruiting |
NCT04852146 -
Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
|
||
Active, not recruiting |
NCT02892903 -
In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?
|
N/A | |
Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
Completed |
NCT02944123 -
Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)
|
Phase 3 | |
Completed |
NCT04077229 -
Piloting Text Messages to Promote Positive Affect and Physical Activity
|
N/A | |
Active, not recruiting |
NCT02922140 -
The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit
|
N/A | |
Terminated |
NCT02620202 -
Aiming Towards Evidence Based Interpretation of Cardiac Biomarkers in Patients Presenting With Chest Pain
|